United Therapeutics Corp (NAS:UTHR)
$ 360.87 -2.78 (-0.76%) Market Cap: 16.11 Bil Enterprise Value: 13.18 Bil PE Ratio: 15.85 PB Ratio: 2.64 GF Score: 86/100

United Therapeutics Corp at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 09:30PM GMT
Release Date Price: $264.97 (-4.06%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with United Therapeutics. We are not switching rooms for Q&A. We're going to stay right here. There's a couple of ways you can ask questions. You can raise your hand and someone will bring you a mic. You can enter it electronically on a portal and send it to me on an iPad, and I can ask the management team or you can just listen to me ask questions. But hopefully, you have some of your own.

Well, anyway, with that, let me pass it over to United Therapeutics Chairperson and CEO, Martine Rothblatt, for the presentation.

Martine A. Rothblatt
United Therapeutics Corporation - Founder, Chairman & CEO

Thank you, Jess. Thank you, everybody. I'd like to start our presentation by just saying a comment about the company's tagline, enabling inspiration. As a CEO, when I think about what my fundamental job is at United

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot